RESEARCH TRIANGLE PARK, N.C., Jan. 30 /PRNewswire/ -- AlphaVax has
assembled its Cytomegalovirus (CMV) Advisory Board to provide expertise and
advice as the company moves its CMV vaccine candidates through clinical
development. To be chaired by Dr. Robert Olmsted, AlphaVax's Vice President
for Research, the Board members include:
-- Mark Schleiss, MD, Professor, Associate Head for Research and the
American Legion Chair in the Department of Pediatrics and Director,
Division of Infectious Diseases, at the University of Minnesota.
-- David Bernstein, MD, Albert Sabin Professor of Pediatrics, Director,
Infectious Diseases and Director of the Gamble Program at the
Cincinnati Children's Hospital and Medical Center.
-- Robert Pass, MD, Professor, Pediatrics and Microbiology at the
University of Alabama - Birmingham.
-- Paul D. Griffiths, MD, DSc, Professor and Head of the Centre for
Virology, Division of Infection at Royal Free and University College
Medical School in London.
AlphaVax is pleased to have these distinguished researchers and clinicians in the field of cytomegalovirus provide their perspectives on advancing an alphavirus vectored CMV vaccine. "We look forward to working with our CMV Advisory Board to help design and implement post-Phase I clinical programs for assessing the potential of our CMV vaccine candidates in transplant indications, prevention of mother-to-child transmission, and prophylactic adolescent immunization," said Dr. Olmsted.
AlphaVax, Inc. is a North Carolina-based, clinical-stage company that
uses a novel alphavirus vector platform technology that has proven to be
highly flexible and immunogenic, and allows the same manufacturing,
formulation, and delivery strategies to be applied to many different
products. In addition to programs in influenza and cytomegalovirus,
important disease targets include cance
|SOURCE AlphaVax, Inc.|
Copyright©2008 PR Newswire.
All rights reserved